{"public_id":"cl_4e91cc4245f3e2b6433fa2dff8654c1d","status":"active","superseded_by_public_id":null,"corpus_id":382332,"text":"Greater than 80% inhibition of ERK phosphorylation in patient tumours correlated with clinical response at higher exposure achieved by the amorphous formulation.","confidence":0.93,"paper":{"corpus_id":382332,"title":"Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma","url":"https://sah.borca.ai/papers/382332"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.93,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_115c35c0e816966a63ddb34b6e24e069","name":"amorphous drug formulation","description":"A non-crystalline formulation used to achieve higher drug exposure.","types":["formulation"],"url":"https://sah.borca.ai/concepts/co_115c35c0e816966a63ddb34b6e24e069"},{"public_id":"co_1639a2d15bb5d5f12f598594d1e547c7","name":"ERK phosphorylation","description":"Phosphorylation of ERK used here as a biomarker of pathway inhibition.","types":["biomarker","molecular measurement"],"url":"https://sah.borca.ai/concepts/co_1639a2d15bb5d5f12f598594d1e547c7"},{"public_id":"co_c55405f6ecc86b994b11bbf5bf27200b","name":"clinical response","description":"A favorable patient outcome measured by tumor response to treatment.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_c55405f6ecc86b994b11bbf5bf27200b"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_4e91cc4245f3e2b6433fa2dff8654c1d"}